Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses (Q37748492)

22 August 2017

1 reference

title

Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses (English)

1 reference

22 August 2017

1 reference

Danylo Sirskyj

1 reference

22 August 2017

Francisco Diaz-Mitoma

1 reference

22 August 2017

Ashkan Golshani

1 reference

22 August 2017

Ashok Kumar

1 reference

22 August 2017

Ali Azizi

1 reference

22 August 2017

publication date

11 May 2010

1 reference

Immunology & Cell Biology

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

81-89

1 reference

Application of pharmacogenomics to vaccines

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Bioinformatics for Vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

From genome to vaccine—new immunoinformatics tools for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Immunomics: discovering new targets for vaccines and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Prediction of MHC class I binding peptides, using SVMHC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Quantitative prediction of mouse class I MHC peptide binding affinity using support vector machine regression (SVR) models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

SVRMHC prediction server for MHC-binding peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Predictive Bayesian neural network models of MHC class II peptide binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Statistical deconvolution of enthalpic energetic contributions to MHC-peptide binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Towards the chemometric dissection of peptide--HLA-A*0201 binding affinity: comparison of local and global QSAR models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Diversity considerations in HIV-1 vaccine selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

The remarkable frequency of human immunodeficiency virus type 1 genetic recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

A "universal" human influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Reverse vaccinology: a genome-based approach for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Reverse Vaccinology and Genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Model-based design of growth-attenuated viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Old and new vaccine approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Viral peptide immunogens: current challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

More than one reason to rethink the use of peptides in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

T cell recognition of hepatitis B and C viral antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

A speculative view of immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Antigen presentation in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

21 January 2018

HIV vaccine strategies

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

HIV vaccines: new frontiers in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Potency of cell-mediated immune responses to different combined HIV-1 immunogens in a humanized murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Synergistic effect of combined HIV/HCV immunogens: a combined HIV-1/HCV candidate vaccine induces a higher level of CD8+ T cell-immune responses in HLA-A2.1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Harnessing bioinformatics to discover new vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

CEP: a conformational epitope prediction server.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Prediction of residues in discontinuous B-cell epitopes using protein 3D structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Mapping epitopes on protein surfaces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Prediction of three-dimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

An in silico method using an epitope motif database for predicting the location of antigenic determinants on proteins in a structural context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Benchmarking B cell epitope prediction: underperformance of existing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Antibody-protein interactions: benchmark datasets and prediction tools evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

A semi-empirical method for prediction of antigenic determinants on protein antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

In silico predicted conserved B-cell epitopes in the merozoite surface antigen-2 family of B. bovis are neutralization sensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Ab and T cell epitopes of influenza A virus, knowledge and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Conservation of gene order: a fingerprint of proteins that physically interact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Assigning protein functions by comparative genome analysis: Protein phylogenetic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

MULTIPROSPECTOR: an algorithm for the prediction of protein-protein interactions by multimeric threading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

PreSPI: a domain combination based prediction system for protein-protein interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

The Database of Interacting Proteins: 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Predicting protein-protein interactions based only on sequences information

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Global investigation of protein-protein interactions in yeast Saccharomyces cerevisiae using re-occurring short polypeptide sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Systematic discovery of new recognition peptides mediating protein interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Mucosal vaccines: novel advances in technology and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Increased sequence diversity coverage improves detection of HIV-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

7 January 2021

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

7 January 2021

Human intestinal M cells display the sialyl Lewis A antigen.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

7 January 2021

Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

7 January 2021

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

1 reference

https://api.crossref.org/works/10.1038%2FICB.2010.65

7 January 2021

Identifiers

DOI

10.1038/ICB.2010.65

1 reference

22 August 2017

1 reference